Baxter Launches NUMETA G13E in Europe: Only Ready-To-Use IV Nutrition for Vulnerable Preterm Newborns at Risk for Malnutrition
Baxter International Inc. | September 19, 2016
Baxter International Inc. (NYSE: BAX), a global leader in PN therapy, announced the European launch of NUMETA G13E 300 mL, the only ready-to-use parenteral (intravenous) nutrition (PN) product available to treat preterm infants (less than 37 weeks gestation age) who are at high risk for infection and malnutrition1 in the early hours and days of their lives.